Back to Browse Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice

Authors Lee S, Kim MS, Lee D, Kwon TK, Khang D, Yun HS, Kim SH

Received 24 October 2012

Accepted for publication 24 November 2012

Published 7 January 2013 Volume 2013:8(1) Pages 147—158

DOI https://dx.doi.org/10.2147/IJN.S39534

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Soyoung Lee,1,* Mi-Sun Kim,1,* Dakeun Lee,2 Taeg Kyu Kwon,3 Dongwoo Khang,4 Hui-Suk Yun,5 Sang-Hyun Kim1

1CMRI, Laboratory of Immunotoxicology, Department of Pharmacology,School of Medicine, Kyungpook National University, Daegu, Republic of Korea; 2Department of Pathology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; 3Department of Immunology, School of Medicine, Keimyung University, Daegu, Republic of Korea; 4School of Nano and Advanced Materials Science and Engineering, Gyeongsang National University, Jinju, Republic of Korea; 5Engineering Ceramics Department, Powder and Ceramics Division, Korea Institute of Materials Science, Changwon, Republic of Korea

*These authors contributed equally to this work

Background: Mesoporous silica (MPS) nanoparticles (NPs), which have a unique pore structure and extremely large surface area and pore volume, have received much attention because of their biomedical application potential. Using MPS NPs for biomedical devices requires the verification of their biocompatibility because the surface area of NPs is one of the most important determinants of toxicity, including the cellular uptake and immune response. We have previously reported that the cytotoxicity and inflammation potential of MPS NPs have been shown to be lower than those of general amorphous colloidal silica (Col) NPs in macrophages, but the low cytotoxicity does not guarantee high biocompatibility in vivo. In this study, we compared the in vivo immunotoxicity of MPS and Col NPs in the mouse model to define the effects of pore structural conditions of silica NPs.
Materials and methods: Both MPS and Col NPs (2, 20, and 50 mg/kg/day) were intraperitoneally administered in female BALB/c mice for 4 weeks, and clinical toxicity, lymphocyte population, serum IgG/IgM levels, and histological changes were examined.
Results: There was no overt sign of clinical toxicity in either MPS- or Col-treated mice. However, MPS NPs led to significant increases in liver and spleen weight and splenocyte proliferation. Mice treated with MPS NPs showed altered lymphocyte populations (CD3+, CD45+, CD4+, and CD8+) in the spleen, increased serum IgG and IgM levels, and histological changes. Despite slight changes in lymphocyte populations in the spleen, Col NPs did not alter other immunological factors.
Conclusion: The results indicate that in vivo exposure to MPS NPs caused more damage to systemic immunity than that of Col NPs through the dysregulation of the spleen. The results for in vivo data are inconsistent with those for in vitro data, which show lower cytotoxicity for MPS NPs. These results suggest the importance of verifying biocompatibility both in vitro and in vivo during the design of new nanomaterials.

Keywords: immunotoxicity, mesoporous silica nanoparticle, colloidal silica nanoparticle, spleen

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo

Chen M, Gao X, Wang Y, Chen H, He B, Li Y, Han J, Zhang Z

International Journal of Nanomedicine 2013, 8:4265-4276

Published Date: 6 November 2013

Response to vitamin D and depression in geriatric primary care patients

Muc-Wierzgoń M, Nowakowska-Zajdel E, Klakla K, Dzięgielewska-Gęsiak S, Fatyga E, Kokot T

Clinical Interventions in Aging 2013, 8:825-827

Published Date: 3 July 2013

Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4

Shiozaki Y, Kitajima T, Mazaki T, Yoshida A, Tanaka M, Umezawa A, Nakamura M, Yoshida Y, Ito Y, Ozaki T, Matsukawa A

International Journal of Nanomedicine 2013, 8:1349-1360

Published Date: 9 April 2013

Nonviral gene therapy in vivo with PAM-RG4/apoptin as a potential brain tumor therapeutic

An S, Nam K, Choi S, Bai CZ, Lee Y, Park JS

International Journal of Nanomedicine 2013, 8:821-834

Published Date: 25 February 2013

Highly biocompatible, nanocrystalline hydroxyapatite synthesized in a solvothermal process driven by high energy density microwave radiation

Smolen D, Chudoba T, Malka I, Kedzierska A, Lojkowski W, Swieszkowski W, Kurzydlowski KJ, Kolodziejczyk-Mierzynska M, Lewandowska-Szumiel M

International Journal of Nanomedicine 2013, 8:653-668

Published Date: 12 February 2013

Biocompatibility of Fe3O4@Au composite magnetic nanoparticles in vitro and in vivo

Li Y, Liu J, Zhong Y, Zhang J, Wang Z, Wang L, An Y, Lin M, Gao Z, Zhang D

International Journal of Nanomedicine 2011, 6:2805-2819

Published Date: 9 November 2011

Type I interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma

Tomiyama Y, Yoshioka N, Yanai Y, Kawase T, Nishina S, Hara Y, Yoshida K, Korenaga K, Korenaga M, Hino K

Hepatic Medicine: Evidence and Research 2011, 3:45-52

Published Date: 26 April 2011